Survival in operable non-small-cell lung cancer: Role of p53 mutations, tobacco smoking and asbestos exposure

✍ Scribed by Thanos Sioris; Kirsti Husgafvel-Pursiainen; Antti Karjalainen; Sisko Anttila; Annamaria Kannio; Jarmo A. Salo; Vesa Perhoniemi; Lasse Heikkilä; Harri Vainio

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: French
• Weight: 68 KB
• Volume: 86
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(20000515)86:4<590::aid-ijc23>3.0.co;2-e

✦ Synopsis

Validated markers are needed to identify operable lung cancer patients with poor prognosis. About one-half of nonsmall-cell lung cancers (NSCLCs) carry a mutation in the p53 tumor-suppressor gene. We examined 101 NSCLC patients for surgical stage, completeness of resection, tobacco smoking, asbestos exposure, age, gender and p53 gene mutations as prognostic factors after a follow-up period of 4 years. Coxs multivariate regression model was applied to quantify the associations with overall and cancer-related survival. Patients with a wild-type p53 gene had an overall 4-year survival of 43% and those with a mutated p53 gene, 35%. In squamouscell carcinoma, stage and heavy smoking, defined as the median of pack-years smoked, had prognostic significance for overall survival. Only stage was associated with poor cancerrelated survival. Asbestos exposure was not associated with overall survival or cancer-related survival in squamous-cell carcinoma or adenocarcinoma. In adenocarcinoma, p53 mutation, in addition to stage, emerged as a significant predictor of poor cancer-related survival. Int.